Area of research
Pathology and Forensic Medicine · Pulmonary and Respiratory Medicine
Research interest
Research focused on Guideline and Docetaxel, with related work in Crizotinib, Nintedanib, Procalcitonin. Notable publications include 'Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer', 'Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016', and 'ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability'.
Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study
Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie – Update 2021
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course
<i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
Biomarkers in community-acquired pneumonia